Stockscreener 앱 받기
72.29
0.01%
0.01
전일 마감가:
$72.28
열려 있는:
$72.65
하루 거래량:
333.92K
Relative Volume:
0.95
시가총액:
$1.66B
수익:
$923.71M
순이익/손실:
$84.68M
주가수익비율:
18.34
EPS:
3.9419
순현금흐름:
$182.81M
1주 성능:
-2.17%
1개월 성능:
-1.77%
6개월 성능:
-7.40%
1년 성능:
-21.38%
1일 변동 폭
$71.50
$73.08
1주일 범위
$69.90
$74.28
52주 변동 폭
$69.58
$97.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(609) 759-1810
주소
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
72.29 | 1.66B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-23 | 개시 | Oppenheimer | Perform |
| 2026-09-09 | 개시 | Leerink Partners | Outperform |
| 2026-07-17 | 개시 | Canaccord Genuity | Hold |
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance
Form 4 ANI Pharmaceuticals Inc For: 1 October By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $208,050 in stock - Investing.com
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares - MarketBeat
After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANI Pharmaceuticals Announces New Fluocinolone Acetonide - GlobeNewswire
Data on an eye implant for chronic eye inflammation will be presented in a late-breaking talk Oct. 9. - Stock Titan
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo Finance UK
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - TradingView
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo! Finance Canada
183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE - MarketBeat
ANIP5868601 Bond Profile: Coupon and Redemption - TradingView
ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance Singapore
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
ANI Pharmaceuticals gets FDA approval for generic everolimus - Investing.com
Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating - Investing.com
ANI Pharmaceuticals Receives FDA Approval for Generic Everolimus Tablets for Oral Suspension - Quiver Quantitative
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - Yahoo Finance
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire
Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target - Yahoo Finance
ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions - simplywall.st
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth - Eastern Progress
ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares in pre-set trading plan - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) insider lines up $380,000 stock sale for 2026 - Stock Titan
ANI Pharmaceuticals (ANIP) insider sells 500 shares - Stock Titan
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock - Investing.com
ANI Pharmaceuticals (ANIP) director sells 1,000 shares in planned trade - Stock Titan
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan
WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace - Investing.com Canada
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com South Africa
ETFs Investing in ANI Pharmaceuticals, Inc. Stocks - tradingview.com
ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week LowTime to Sell? - MarketBeat
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD - investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board - Yahoo Finance
ANI Pharmaceuticals to Present at September Investor Conferences - The Manila Times
ANI Pharmaceuticals to Present at September Investor Conferences - Yahoo Finance
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ani Pharmaceuticals Inc 주식 (ANIP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Oct 13 '26 |
Sale |
73.59 |
500 |
36,795 |
73,424 |
| CAREY STEPHEN P. | SVP & CFO |
Sep 29 '26 |
Sale |
73.00 |
2,850 |
208,050 |
168,993 |
| Lalwani Nikhil | PRESIDENT & CEO |
Sep 15 '26 |
Sale |
71.00 |
5,400 |
383,400 |
339,089 |
| NIKHIL LALWANI | Director |
Sep 15 '26 |
Proposed Sale |
70.40 |
5,400 |
380,160 |
0 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Sep 14 '26 |
Sale |
70.79 |
500 |
35,395 |
73,924 |
| JEANNE THOMA | Director |
Sep 11 '26 |
Proposed Sale |
71.46 |
1,000 |
71,460 |
0 |
| Thoma Jeanne | Director |
Sep 11 '26 |
Sale |
71.53 |
1,000 |
71,530 |
26,762 |
| CAREY STEPHEN P. | SVP & CFO |
Aug 31 '26 |
Sale |
72.80 |
2,850 |
207,480 |
171,843 |
| Lalwani Nikhil | PRESIDENT & CEO |
Aug 25 '26 |
Sale |
74.30 |
5,400 |
401,220 |
344,489 |
| NIKHIL LALWANI | Director |
Aug 25 '26 |
Proposed Sale |
74.17 |
5,400 |
400,518 |
0 |
2.21%
5.84%
자본화:
|
볼륨(24시간):